Form 8-K Regulus Therapeutics For: Jan 27
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
- After-Hours Movers: WDC, BE, DECK, FIX, RNG
Needham & Company Downgrades Regulus Therapeutics (RGLS) to Hold
January 30, 2017 7:28 AM ESTNeedham & Company downgraded Regulus Therapeutics (NASDAQ: RGLS) from Buy to Hold.
Analyst Alan Carr commented, "RGLS announced late Friday that FDA has extended RG-101 clinical hold and requested additional long-term clinical data from ongoing trials. These data are not expected until 4Q17.... More



